Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQLNASDAQ:HALONASDAQ:MDGLNASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQLArQule$20.00$20.00$3.15▼$20.45$2.42B2.495.27 million shsN/AHALOHalozyme Therapeutics$54.05+0.4%$55.61$42.01▼$70.51$6.66B1.151.75 million shs868,065 shsMDGLMadrigal Pharmaceuticals$298.49-0.6%$291.84$200.63▼$377.46$6.63B-1.05358,926 shs108,674 shsRGENRepligen$127.36+0.3%$127.05$102.97▼$182.52$7.16B1.11728,834 shs208,766 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQLArQule0.00%0.00%0.00%0.00%0.00%HALOHalozyme Therapeutics+0.39%+2.89%+1.39%-9.57%+3.92%MDGLMadrigal Pharmaceuticals-0.55%-0.34%+4.95%-5.06%+9.87%RGENRepligen+0.32%+2.54%+2.38%+13.78%+5.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQLArQuleN/AN/AN/AN/AN/AN/AN/AN/AHALOHalozyme Therapeutics4.8516 of 5 stars3.11.00.04.42.62.54.4MDGLMadrigal Pharmaceuticals4.1117 of 5 stars3.40.00.04.62.23.30.6RGENRepligen4.8194 of 5 stars4.32.00.04.52.91.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQLArQule 0.00N/AN/AN/AHALOHalozyme Therapeutics 2.17Hold$61.9014.52% UpsideMDGLMadrigal Pharmaceuticals 2.89Moderate Buy$420.6340.92% UpsideRGENRepligen 2.69Moderate Buy$172.8335.70% UpsideCurrent Analyst Ratings BreakdownLatest ARQL, RGEN, MDGL, and HALO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025RGENRepligenBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$150.005/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/14/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.005/13/2025HALOHalozyme TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/13/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform$47.005/7/2025HALOHalozyme TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2025HALOHalozyme TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $65.005/5/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQLArQule$25.76M93.85N/AN/A$0.72 per share27.78HALOHalozyme Therapeutics$1.02B6.56$4.67 per share11.57$2.86 per share18.90MDGLMadrigal Pharmaceuticals$180.13M36.79N/AN/A$34.59 per share8.63RGENRepligen$634.44M11.28$3.12 per share40.87$35.21 per share3.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQLArQule-$15.48M-$0.16N/AN/AN/A-805.61%-33.10%-26.87%N/AHALOHalozyme Therapeutics$444.09M$3.7614.388.690.3644.76%136.91%26.05%8/5/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)RGENRepligen-$25.51M-$0.45N/A53.973.63-3.93%4.53%3.17%7/29/2025 (Estimated)Latest ARQL, RGEN, MDGL, and HALO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025RGENRepligen$0.40N/AN/AN/A$174.62 millionN/A5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 million5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQLArQuleN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQLArQule0.088.278.27HALOHalozyme Therapeutics3.138.397.30MDGLMadrigal Pharmaceuticals0.175.915.58RGENRepligen0.276.795.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQLArQule74.63%HALOHalozyme Therapeutics97.79%MDGLMadrigal Pharmaceuticals98.50%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipARQLArQule13.80%HALOHalozyme Therapeutics2.40%MDGLMadrigal Pharmaceuticals21.50%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQLArQule36120.87 millionN/AOptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableRGENRepligen1,77856.18 million55.51 millionOptionableARQL, RGEN, MDGL, and HALO HeadlinesRecent News About These Companies1 Healthcare Stock to Target This Week and 2 to Be Wary OfJuly 3 at 6:45 PM | msn.comWCM Investment Management LLC Has $13.74 Million Stock Position in Repligen Corporation (NASDAQ:RGEN)July 3 at 5:38 AM | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $3.98 Million Stake in Repligen Corporation (NASDAQ:RGEN)July 2 at 4:31 AM | marketbeat.comAllspring Global Investments Holdings LLC Purchases 16,421 Shares of Repligen Corporation (NASDAQ:RGEN)June 30, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Downgraded by Wall Street Zen to "Hold"June 30, 2025 | americanbankingnews.comWall Street Zen Downgrades Repligen (NASDAQ:RGEN) to HoldJune 29, 2025 | marketbeat.comArtemis Investment Management LLP Grows Position in Repligen Corporation (NASDAQ:RGEN)June 27, 2025 | marketbeat.comOppenheimer Asset Management Inc. Boosts Position in Repligen Corporation (NASDAQ:RGEN)June 27, 2025 | marketbeat.comBessemer Group Inc. Buys 4,325 Shares of Repligen Corporation (NASDAQ:RGEN)June 26, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Coverage Initiated at BarclaysJune 26, 2025 | americanbankingnews.com5 Insightful Analyst Questions From Repligen’s Q1 Earnings CallJune 25, 2025 | msn.comWealthquest Corp Takes Position in Repligen Corporation (NASDAQ:RGEN)June 25, 2025 | marketbeat.comBarclays Initiates Coverage of Repligen (RGEN) with Overweight RecommendationJune 24, 2025 | msn.comRepligen (NASDAQ:RGEN) Earns Overweight Rating from Analysts at BarclaysJune 24, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Raised to Buy at Wall Street ZenJune 21, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Shares Sold by Riverbridge Partners LLCJune 20, 2025 | marketbeat.comConestoga Capital Advisors LLC Purchases 32,665 Shares of Repligen Co. (NASDAQ:RGEN)June 17, 2025 | marketbeat.comTrust Point Inc. Trims Holdings in Repligen Co. (NASDAQ:RGEN)June 17, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Shares Down 3.1% - Should You Sell?June 16, 2025 | marketbeat.comAzzad Asset Management Inc. ADV Acquires Shares of 21,077 Repligen Co. (NASDAQ:RGEN)June 15, 2025 | marketbeat.comDoes Repligen Corp (RGEN) Have a Strong Pricing Power?June 13, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Blockchain Stocks to Profit in a Decentralized WorldBy Chris Markoch | June 24, 2025View 3 Blockchain Stocks to Profit in a Decentralized WorldARQL, RGEN, MDGL, and HALO Company DescriptionsArQule NASDAQ:ARQLArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.Halozyme Therapeutics NASDAQ:HALO$54.05 +0.21 (+0.39%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$54.05 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Madrigal Pharmaceuticals NASDAQ:MDGL$298.48 -1.67 (-0.55%) Closing price 07/3/2025 03:39 PM EasternExtended Trading$298.48 0.00 (0.00%) As of 07/3/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Repligen NASDAQ:RGEN$127.36 +0.40 (+0.32%) Closing price 07/3/2025 01:10 PM EasternExtended Trading$127.36 0.00 (0.00%) As of 07/3/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
